LLY vs RXRX: which is the better buy in 2026?
On Alexandria's Compass, Eli Lilly and Company has the edge with a 92/100 score versus 90/100 for RXRX. Here is how they stack up, factor by factor.
Eli Lilly and Company
NYSE:LLY
Lilly's oral GLP-1 launch turns a supply-constrained blockbuster into a mass-market franchise worth far more than today's price.
Full LLY analysisRecursion Pharmaceuticals
NASDAQ:RXRX
Recursion's AI drug discovery platform is real science, but $208M annual cash burn against a $1.9B market cap demands clinical proof soon.
Full RXRX analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is LLY or RXRX the better buy in 2026?
By Compass Score, Eli Lilly and Company (NYSE:LLY) edges it at 92/100 versus 90/100 for RXRX. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare LLY and RXRX?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.